Allarity Therapeutics (NASDAQ:ALLR) versus Bright Minds Biosciences (NASDAQ:DRUG) Critical Survey

Bright Minds Biosciences (NASDAQ:DRUG) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.

Volatility & Risk

Bright Minds Biosciences has a beta of -6.45, suggesting that its stock price is 745% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bright Minds Biosciences and Allarity Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0	0	4	1	3.20
Allarity Therapeutics	0	0	0	0	0.00

Bright Minds Biosciences currently has a consensus price target of $84.33, indicating a potential upside of 128.86%. Given Bright Minds Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Allarity Therapeutics.

Earnings and Valuation

This table compares Bright Minds Biosciences and Allarity Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$2.06 million	($0.17)	-216.76
Allarity Therapeutics	N/A	N/A	-$11.90 million	N/A	N/A

Insider & Institutional Ownership

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Bright Minds Biosciences and Allarity Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-5.85%	-5.68%
Allarity Therapeutics	N/A	-369.67%	-100.06%

Summary

Bright Minds Biosciences beats Allarity Therapeutics on 9 of the 10 factors compared between the two stocks.

About Bright Minds Biosciences

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.